nasacort aq nasal spray
sanofi-aventis (malaysia) sdn. bhd. - triamcinolone acetonide -
tilade cfc-free
sanofi-aventis new zealand limited - nedocromil sodium 1.4085%{relative} (2 mg/dose); - aerosol inhaler, metered dose - 2 mg/dose - active: nedocromil sodium 1.4085%{relative} (2 mg/dose) excipient: apaflurane macrogol 600 menthol povidone - tilade cfc-free is indicated in the treatment of bronchial asthma (whether extrinsic or intrinsic in nature, and including asthmatic bronchitis, late onset asthma, exercise induced asthma, and bronchospasm provoked by a variety of stimuli such as cold air, inhaled allergens, atmospheric pollutants and other irritants). tilade cfc-free is intended for regular prophylactic treatment and not for symptomatic relief. in the management of asthma, tilade cfc-free improves pulmonary function, reduces the frequency and severity of attacks and reduces bronchospasm, cough and bronchial hyper-responsiveness. in patients already receiving treatment for their asthma, tilade cfc-free can be given in addition to all existing therapies and will in many cases provide added therapeutic benefit. having established this benefit of tilade cfc-free, it may be possible to gradually reduce or eliminate concomitant therapy.
intal 5 inhaler 5 mg/inhalation
sanofi-aventis singapore pte. ltd. - sodium cromoglycate - aerosol, spray - 5 mg/inhalation
lifsar pulmojet 50/500 microgram powder for inhalation
sanofi-aventis ireland limited t/a sanofi - salmeterol xinafoate, fluticasone propionate - powder for inhalation - 50/500 microgram - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics - adrenergics, inhalants; adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics. - lifsar pulmojet is indicated for the symptomatic treatment of adults with chronic obstructive pulmonary disease (copd) with a fev1 < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations and who have significant symptoms despite regular bronchodilator therapy.
imferon
sanofi-aventis new zealand limited - iron dextran 50 mg/ml (iron equivalent) - solution for injection - 100 mg/2ml - active: iron dextran 50 mg/ml (iron equivalent)
lomusol nasal spray
sanofi-aventis new zealand limited - sodium cromoglicate 2%{relative}; - nasal spray solution - 2% w/v - active: sodium cromoglicate 2%{relative} excipient: benzalkonium chloride disodium edetate dihydrate purified water
opticrom
sanofi-aventis new zealand limited - sodium cromoglicate 4%{relative} (micronised) - eye ointment - 4% w/v - active: sodium cromoglicate 4%{relative} (micronised) excipient: lanolin liquid paraffin yellow soft paraffin
rynacrom nasal drops
sanofi-aventis new zealand limited - sodium cromoglicate 2%{relative}; - nasal drops - 2 % - active: sodium cromoglicate 2%{relative} excipient: benzalkonium chloride disodium edetate dihydrate purified water
rynacrom nasal spray
sanofi-aventis new zealand limited - sodium cromoglicate 2%{relative}; - nasal spray solution - 2 % - active: sodium cromoglicate 2%{relative} excipient: benzalkonium chloride disodium edetate dihydrate purified water
nasacort hfa triamcinolone acetonide aerosol metered
aventis pharmaceuticals inc. - triamcinolone acetonide (unii: f446c597ka) (triamcinolone - unii:1zk20vi6ty) - 55 ug